At each visit: Weight and body composition measurements Blood pressure and heart rate Appetite and appetite suppression assessment GI tolerance and other side effects Medication adherence and injection technique Protein intake and exercise consistency Laboratory monitoring occurs at Month 3 (comprehensive panel), Month 6, and Month 12, then annually
Therefore, BMP4 becomes a potential therapeutic target in CRC, especially in a diabetic context where high blood glucose significantly affects cancer progression through the BMP4 pathway.519 Ultimately, GLP-1RA, by regulating BMP4 and its effects on cell proliferation and metastasis, provides a promising treatment approach.519 This not only demonstrates the role of GLP-1RA in diabetes management but also offers potential for integrating diabetes and cancer treatment.520 This finding emphasizes the importance of considering metabolic status in cancer treatment and the necessity for further research in this area.519 While early models have shown promising results, the application of GLP-1RAs in cancer treatment has not yet been established and requires further clinical trials.527 Conclusions and perspective Primarily recognized for their role in diabetes mellitus treatment, GLP-1RAs have demonstrated significant benefits in cardiovascular health, skeletal muscle-related diseases, obesity management, and neurodegenerative conditions, among others
Medicine 1991;70:22945
The right cadence depends on what you are treating and how your body responds between sessions
